Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience

Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience

Background: Interleukin 23 (IL-23) inhibitors, such as guselkumab, risankziumab, and tildrakizumab, have proved to be highly effective and safe for psoriasis treatment either in bio-naïve or bio-experienced patients. A substantial proportion of patients show a primary or secondary inefficacy to IL-1...

Full description

Bibliographic Details
Main Authors: Silvia Giordano, Paolo Dapavo, Michela Ortoncelli, Elena Stroppiana, Anna Verrone, Pietro Quaglino, Simone Ribero, Luca Mastorino
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Journal of Clinical Medicine
Subjects:
psoriasis
IL23 inhibitors
IL17 inhibitors
PASI
switch
switching
Online Access:https://www.mdpi.com/2077-0383/12/24/7503

Internet

https://www.mdpi.com/2077-0383/12/24/7503

Similar Items